cancer news

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

by

Lung Cancer – stock.adobe.com Frontline treatment with the PD-1 inhibitor cemiplimab-rwlc (Libtayo) led to improvements in progression-free survival (PFS) and overall survival (OS) vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with brain metastases and a confirmed PD-L1 expression of at least 50%, according to data from an exploratory subgroup analysis of … Read more

Brain Imaging Plus Virtual Reality Shows Promise for Effectively Managing Cancer Pain

by

Oscar de Leon-Casaola, MD A clinical research study led by Roswell Park Comprehensive Cancer Center has identified a way to objectively measure pain in cancer patients and treat it effectively without opioids. Published in Scientific Reports, the study advances the goal of better managing cancer pain using a non-invasive brain imaging technology and a non-drug … Read more

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

by

Sheela Rao, MBBS, MD, FRCP Advances in the treatment of anal cancer including refined chemoradiotherapy regimens and the introduction of immunotherapy-based approaches have further improved outcomes, however a lack of focus on early detection has contributed to rising incidence rates, underscoring the importance of disease awareness among patients and health care providers, according to Sheela … Read more

Tisotumab Vedotin Boosts Survival in Chinese Subpopulation With Previously Treated Cervical Cancer

by

Archyde in a ⁤meaningful breakthrough for cervical cancer treatment, tisotumab vedotin-tftv, known as Tivdak, has shown remarkable efficacy in improving overall survival (OS) among patients with‍ recurrent ⁣or metastatic cervical cancer.This groundbreaking revelation stems from⁢ the phase 3 innovaTV 301 study (NCT04697628), which⁢ focused on a⁤ specific subpopulation in ⁢China. Beyond the improvement in survival … Read more

ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL

by

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas were updated to include circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) assessment for patients with PET-positive diffuse large B-cell lymphoma (DLBCL) at end of first-line treatment.1,2 This decision marks the first inclusion of ctDNA MRD testing in these … Read more